ArticleThe European respiratory journal2019
Eosinophil-derived IL-13 promotes emphysema.
Article in The European respiratory journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.Clinical drug investigation · 2021Trial
- Preclinical models of COPD: a state of the art review.The European respiratory journal · 2026Review
- Eosinophil biology in COPD: from scientific insight to clinical treatment action.ERJ open research · 2026Review
- Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma.Pulmonary therapy · 2026Review
- From Susceptibility to Disease Severity: Re-Discovering the Clinical Role ofLife (Basel, Switzerland) · 2026Article
- Increased alveolar tissue destruction in a sub-group of COPD patients with increased alveolar septal eosinophil counts.ERJ open research · 2026Article
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Integrated miR-omics and proteomics reveal the regulatory role of miR in protein networks associated with COVID-19 disease progression.Frontiers in immunology · 2026Article
- Biological Therapies in Chronic Obstructive Pulmonary Disease: New Directions in Personalised Respiratory Medicine.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.Respiratory research · 2025Review
- The Role of Interleukin-13 in Chronic Airway Diseases: A Cross-Sectional Study in COPD and Asthma-COPD Overlap.Diseases (Basel, Switzerland) · 2025Article
- Eosinophilic cytokines and small airway dysfunction in women with COPD: correlation with exposure to biomass smoke versus tobacco smoking.IJTLD open · 2025Article
- The COURSE trial and beyond: rethinking chronic obstructive pulmonary disease exacerbation management with biologics.Journal of thoracic disease · 2025Article
- Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.Pulmonary therapy · 2025Review
- SignallingERJ open research · 2025Article
- Observational
- Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease.Journal of clinical medicine · 2025Article
- Developmental immune network of airway lymphocytes and innate immune cells in patients with stable COPD.Frontiers in immunology · 2025Article
- Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease.Nature reviews. Immunology · 2024Review
- Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
The inflammatory responses in chronic airway diseases leading to emphysema are not fully defined. We hypothesised that lung eosinophilia contributes to airspace enlargement in a mouse model and to emphysema in patients with chronic obstructive pulmonary disease (COPD).A transgenic mouse model of chronic type 2 pulmonary inflammation (I5/hE2) was used to examine eosinophil-dependent mechanisms leading to airspace enlargement. Human sputum samples were collected for translational studies examining eosinophilia and matrix metalloprotease (MMP)-12 levels in patients with chronic airways disease.Airspace enlargement was identified in I5/hE2 mice and was dependent on eosinophils. Examination of I5/hE2 bronchoalveolar lavage identified elevated MMP-12, a mediator of emphysema. We showed,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.